以免疫检查点抑制剂（ICI）为基础的肝细胞癌（HCC）联合治疗模式在临床研究和实践中取得了显着疗效，已成为不可手术切除HCC治疗的中流砥柱。为了更好地帮助临床医生合理使用联合免疫治疗药物和方案，编委会与该领域多学科专家讨论，有效、安全地采用“德尔菲”共识形成方法，最终修订完成了《中国免疫检查点抑制剂（ICIs）联合治疗多学科专家共识》肝细胞癌（2023年版）》是在2021年版的基础上制定的。本共识主要围绕ICIs联合治疗的临床实践原则和方法，旨在根据最新研究和专家的意见总结临床应用建议。经验并为临床医生提供应用指导。© 2024 作者。由巴塞尔 S. Karger AG 出版。

Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC.To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition.This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.© 2024 The Author(s). Published by S. Karger AG, Basel.